US shutdown dampens first-quarter flotations
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
Peanut therapy makers face pricing pushback
An Icer report questioning the cost effectiveness of Aimmune and DBV's peanut allergy projects is yet another reason to be cautious about the companies'…
Galapagos flies with more Finch data
Filgotinib could be the safest Jak inhibitor yet, but Galapagos will need to make the most of this as it squares up to Abbvie.
Upcoming events – Pfizer and Glycomimetics await sickle cell data and Biocryst tries again
Rivipansel needs to help sickle cell patients leave hospital sooner and BCX7353 faces established hereditary angioedema agents.
Go or no go? Abbvie, Glaxo and Heron await FDA verdicts
Notable US regulatory decisions due in April feature a major pipeline hope from Abbvie, a non-opioid pain medication from Heron and Glaxo’s two-pill HIV regimen.
Allergy’s lesson: don’t bet on studies that have been delayed
The long overdue readout of a pivotal birch pollen allergy vaccine trial draws a blank for the beleaguered UK company.
More Sanofi dengue setbacks could benefit Takeda
Sanofi might only get the US go-ahead for its dengue vaccine Dengvaxia in a narrow population, leaving the door open for its rival Takeda.
Xeljanz warning Jaks up safety concerns
An increased risk of blood clots and death with Pfizer’s drug could also bode ill for newer Jak inhibitors.
DBV perseveres with peanut project
DBV plans to refile Viaskin Peanut in the third quarter, but things look all but smooth.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.